CrkL Antibody - #AF7805

(1)   (5)  
Product: CrkL Antibody
Catalog: AF7805
Description: Rabbit polyclonal antibody to CrkL
Application: WB
Reactivity: Human, Mouse, Rat, Monkey
Prediction: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 39kDa; 34kD(Calculated).
Uniprot: P46109
RRID: AB_2844169

View similar products>>

   Size Price Inventory
 50ul $250 In stock
 100ul $350 In stock
 200ul $450 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat,Monkey
Prediction:
Pig(100%), Zebrafish(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(100%)
Clonality:
Polyclonal
Specificity:
CrkL Antibody detects endogenous levels of total CrkL.
RRID:
AB_2844169
Cite Format: Affinity Biosciences Cat# AF7805, RRID:AB_2844169.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Crk L; Crk like protein; Crk-like protein; Crkl; CRKL_HUMAN; Crkol; HGNC:2363; Oncogene CrkL; V crk avian sarcoma virus CT10 oncogene homolog like; v crk sarcoma virus CT10 oncogene homolog (avian) like; V crk sarcoma virus CT10 oncogene homolog avian like;

Immunogens

Immunogen:
Uniprot:

P46109(CRKL_HUMAN) >>Visit HPA database.

Gene(ID):
CRKL(1399)
Sequence:
MSSARFDSSDRSAWYMGPVSRQEAQTRLQGQRHGMFLVRDSSTCPGDYVLSVSENSRVSHYIINSLPNRRFKIGDQEFDHLPALLEFYKIHYLDTTTLIEPAPRYPSPPMGSVSAPNLPTAEDNLEYVRTLYDFPGNDAEDLPFKKGEILVIIEKPEEQWWSARNKDGRVGMIPVPYVEKLVRSSPHGKHGNRNSNSYGIPEPAHAYAQPQTTTPLPAVSGSPGAAITPLPSTQNGPVFAKAIQKRVPCAYDKTALALEVGDIVKVTRMNINGQWEGEVNGRKGLFPFTHVKIFDPQNPDENE

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Xenopus
100
Zebrafish
100
Chicken
100
Rabbit
100
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P46109 As Substrate

Site PTM Type Enzyme
R11 Methylation
S41 Phosphorylation
S42 Phosphorylation
T43 Phosphorylation
C44 S-Nitrosylation
Y48 Phosphorylation
Y92 Phosphorylation
T95 Phosphorylation
T96 Phosphorylation
T97 Phosphorylation
S107 Phosphorylation
S112 Phosphorylation
S114 Phosphorylation
Y127 Phosphorylation
T130 Phosphorylation
Y132 Phosphorylation
K145 Ubiquitination
Y177 Phosphorylation
K180 Acetylation
K180 Ubiquitination
S184 Phosphorylation
S185 Phosphorylation
S195 Phosphorylation
S197 Phosphorylation
Y198 Phosphorylation
Y207 Phosphorylation A9UF07 (BCR/ABL fusion) , A0A173G4P4 (Abl fusion) , P00519 (ABL1)
T212 Phosphorylation
T213 Phosphorylation
T214 Phosphorylation
S220 Phosphorylation
S222 Phosphorylation
T228 Phosphorylation
S232 Phosphorylation
Y251 Phosphorylation
K253 Acetylation
K253 Ubiquitination
T254 Phosphorylation
K283 Ubiquitination
K292 Ubiquitination

Research Backgrounds

Function:

May mediate the transduction of intracellular signals.

Subunit Structure:

Interacts with tyrosine-phosphorylated EPOR and INPP5D/SHIP1. Interacts with DOCK2 and DOCK5 via its first SH3 domain. Interacts with phosphorylated CBLB and IRS4.

Family&Domains:

Belongs to the CRK family.

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Bacterial invasion of epithelial cells.

· Human Diseases > Infectious diseases: Bacterial > Shigellosis.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc gamma R-mediated phagocytosis.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

References

1). Silencing of the CrkL gene reverses the doxorubicin resistance of K562/ADR cells through regulating PI3K/Akt/MRP1 signaling. JOURNAL OF CLINICAL LABORATORY ANALYSIS (PubMed: 34114685) [IF=2.7]

Application: WB    Species: Human    Sample: K562/ADR cells

FIGURE 5 Effects of CrkL silencing on nude mice burdened with K562/ADR xenografts. A xenograft tumor model was established via subcutaneously injecting K562/ADR cells. (A) Tumor image was shown in each group. (B-C). The growth curves and weights of the tumors in each group were measured. Silencing CrkL notably inhibited the tumor growth compared with NC group. (D-E) The images of Ki67-IHC were shown in each group and the Ki67 positive staining area was measured. The Ki67 positive staining area of CrkL siRNA treatment was lower compared with the NC group. (F-G) Western blot assay was performed to determine PI3K/AKT/MRP1 pathway-related proteins expression. CrkL silencing in vivo significantly suppressed p-AKT, CrkL, MRP1 protein levels while AKT expression remained unchanged compared with the control and NC groups. The data were represented as mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ns means not significant, p > 0.05

Application: IHC    Species: Human    Sample: K562/ADR cells

FIGURE 5 Effects of CrkL silencing on nude mice burdened with K562/ADR xenografts. A xenograft tumor model was established via subcutaneously injecting K562/ADR cells. (A) Tumor image was shown in each group. (B-C). The growth curves and weights of the tumors in each group were measured. Silencing CrkL notably inhibited the tumor growth compared with NC group. (D-E) The images of Ki67-IHC were shown in each group and the Ki67 positive staining area was measured. The Ki67 positive staining area of CrkL siRNA treatment was lower compared with the NC group. (F-G) Western blot assay was performed to determine PI3K/AKT/MRP1 pathway-related proteins expression. CrkL silencing in vivo significantly suppressed p-AKT, CrkL, MRP1 protein levels while AKT expression remained unchanged compared with the control and NC groups. The data were represented as mean ± SD of three independent experiments. *p < 0.05, **p < 0.01, ns means not significant, p > 0.05

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.